1 Myeloma Plasma Cell Disorders (Schema Name: MyelomaPlasmaCellDisorder) V0203.

Slides:



Advertisements
Similar presentations
Instructions and Reporting Requirements Module 11 Electronic Reporting For Urology Physician Practices May 2013 North Carolina Central Cancer Registry.
Advertisements

Hematopoietic and Lymphoid Neoplasm Project. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
STAGING MCR Staff Show Me Healthy Women March 27, 2008 Supported by a Cooperative Agreement between DHSS and the Centers for Disease Control and Prevention.
Esophagus, Esophagus GE Junction, Stomach
1 Renal Pelvis, Ureter, Bladder and Other Urinary.
Hematopoietic Database and Manual
Hematopoietic and Lymphoid Neoplasm Project. Primary Site and Histology Rules Steven Peace, BS, CTR Westat October 2009.
CS Evaluation Fields Education and Training Team Collaborative Stage Data Collection System Version (Effective date: 1/1/2011)
The Anatomy of Collaborative Staging: Ovary Presentation developed by Collaborative Staging Steering Committee 2005 Update.
Cancer Registry Coding Changes for 2014 Presented by the Kentucky Cancer Registry February, 2014.
Coding Pitfalls Jessica K. Dohler, BS, CTR. Objectives 0 Know how to code the Tumor/Ext Eval code when using intraoperative findings 0 Know when to code.
Jessica K. Dohler, BS, CTR. Need for Change  Complicated Site Specific Grading No easy conversion to available codes Need for special guidelines 
2010 Hematopoietic and Lymphoid Neoplasm Project Issues, Timing and Transformations.
Collaborative Stage Version An Update From Martin Madera CS Program Administrator.
2010 Hematopoietic and Lymphoid Neoplasm Project Maneuvering the Hemato DB and Rules.
Hematopoietic and Lymphoid Neoplasm Project. Primary Site and Histology Rules Peggy Adamo, RHIT, CTR NCI SEER October 2009.
Bladder, Kidney Parenchyma and Testis
Cancer Staging. What is cancer staging? Staging describes the severity of a person’s cancer based on the extent of the original (primary) tumor and whether.
Mississippi Cancer Registry Deirdre B. Rogers, MS Director Mississippi Cancer Registry.
TRAM Educational Conference September 19, 2014 Meritus Medical Center 1.
Directly Coded Summary Stage
Hematopoietic and Lymphoid Neoplasm Project. Background Peggy Adamo, RHIT, CTR NCI SEER September 2009.
H Nèji, H Abid, A Mâalej, S Haddar, R Akrout*, M Ezzeddine*, S Baklouti*, Z Mnif**, J Mnif Imaging department Habib Bourguiba Hospital, *Rheumatology department.
1 Breast MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
Coding Factoids and Frequently Asked Questions Education & Training Team Collaborative Stage Data Collection System Version 1 (CSv2)
1 LUNG. 2 Equivalent Terms, Def, Charts, Tables, Illustrations.
1 MP/H Coding Rules General Instructions MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
2010 Hematopoietic and Lymphoid Neoplasm Project Registry Operations and the SEER Program.
Cancer Staging.
Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012.
CSv2 101 Education & Training Team Collaborative Stage Data Collection System Lecture Version 1.0.
Hematopoietic and Lymphoid Neoplasm Project. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
EVALUATION OF LYMPH NODES & PATHOLOGIC EXAMINATION FOR BREAST CASES Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry.
Head and Neck MP/H Task Force Multiple Primary Rules
1 Head and Neck. 2 Equivalent Terms, Definitions, Charts, Tables and Illustrations Primary site –Do not code biopsy site.
Plasma cell disorders Dr. hassanali vahedian ardakani Medical oncologist hematologist 2013.
VS. CSv2 Changes CSv2 compared to CSv1 Part 1, Section 1.
KCR SPRING TRAINING 2014 New ICD-O-3 Terminology.
2015 CHANGES IN REPORTING REQUIREMENTS AND CANCER CODING INSTRUCTIONS KENTUCKY CANCER REGISTRY SPRING TRAINING 2015 PRESENTED BY FRANCES ROSS.
1 Cutaneous Melanoma MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
Hematopoietic and Lymphoid Neoplasm Project. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
Agency/Standard Setter Updates OSCaR Fall Educational Workshop Claudia Cooksie, RHIT,CTR October 9, 2015 Portland, Oregon.
PUBLIC HEALTH DIVISION Oregon State Cancer Registry Abstracting Hematologic Malignancies Stepping Up Your Game LeeLa Coleman, CTR Cancer Data Consultant.
KCR 2014 Spring Training CHANGES IN CODING GRADE.
Multiple Myeloma Morning Report July 21, 2009 Lindsay Kruska.
New Data Items MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
2010 Hematopoietic and Lymphoid Neoplasm Project Training, Tools and Resources.
Pathology.
Collaborative Staging for Colon Site Specific Factors Tonya Brandenburg, MHA, CTR QA Manager Abstracting and Coding Kentucky Cancer Registry.
Treatment of thyroid nodules Depends on: –FNA cytological examination –Uptake of radioiodine –Size and patient preferences.
*Be brief, yet thorough enough to allow recoding of the data fields from the text only! * Use accepted abbreviations from Abstractor’s Manual Appendix.
CSv2 for the Hematopoietic Neoplasms 1. 2 This includes five schemas …. Hematopoietic, Reticuloendothelial, Immunopro-liferative and Myeloproliferative.
BY FRANCES ROSS, CTR PRESENTED AT THE NAACCR ANNUAL CONFERENCE JUNE, 2008 Record Consolidation Test with the 2007 Multiple Primary/Histology Rules.
1 Virginia Cancer Registrars Association and Virginia Cancer Registry Annual Meeting October 3, 2007.
1. Multiple Primary and Histology Rules 101 Format of MP/H Materials.
Staging System and Excision Types Tae Won Kim, MD PCOM Tumor Review
NPCR Data Completeness and Quality Audits Review of: Collaborative Stage and Surgery Data Mary Lewis, CTR NPCR Program Consultant.
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma Bart Barlogie, Guido J. Tricot, Frits van Rhee, Edguardo Angtuaco,
2016 Edits.
Kentucky Cancer Registry
Tumor Grade.
SEER Case Consolidation Study: Design & Objective
Automated Consolidation of Collaborative Stage Data Items
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual
What’s New for 8th Edition
Cancer Staging.
SEER EOD and Summary Stage
The Progress of npcr audits What have we done, what have we learned, and where are we going now Click to edit subtitle Click to enter your Division Name.
Text Mining for Data Quality Analysis of Melanoma Tumor Depth
Presentation transcript:

1 Myeloma Plasma Cell Disorders (Schema Name: MyelomaPlasmaCellDisorder) V0203

2 Learning Objectives Understand rationale behind changes and updates Understand use of codes and reporting Determine proper code use for accurate reporting Understand finding specific documentation –SSFs –Coding rules

3 Outline Overview of the schema Review Collaborative Stage data items for schema Describe changes to schema in CSv2

Myeloma Plasma Cell Disorders Schema new to v0203 –Effective for cases diagnosed 1/1/2011+ and/or in v02.03 and after Schema developed based on 2010 Hematopoietic Coding Manual and Database For cases collected prior to CSv02.03 –Automatically converted to new schema 4

Myeloma Plasma Cell Disorders Applicable for histologies: –9731 Plasmacytoma, NOS (except C441, C690, C695- C696) –9732 Multiple myeloma (except C441, C690, C695- C696) –9734 Plasmacytoma, extramedullary (except C441, C690, C695-C696) 5

CS Data Items – Not Applicable CS Tumor Size – Code 988 CS Tumor Size/Ext Eval – Code 9 CS Lymph Nodes – Code 987 –Only for histology's 9731 and 9732 CS Lymph Nodes Eval – Code 9 CS Mets at Dx – Code 98 CS Mets Eval – Code 9 6

CS Extension All cases diagnosed prior to January 1, 2011 and originally coded prior to v0203, are coded to the following codes: –Code 100 Localized disease (9731, 9734) –Code 800 Systemic disease (9731, 9732, 9734) –Code 999 Unknown (9731, 9734) Code 999 is valid in v0203 All extension codes are being retained 7

CS Extension 110: Single plasmacytoma without or unknown soft tissue extension (9731) –Primary site is bone 200: Single plasmacytoma lesion WITH soft tissue extension (9731) –Primary site is bone 300 Single plasmacytoma lesion occurring in tissue other than bone (9734) –Primary site is not bone 8

CS Extension 400 Multiple osseous or multiple extraosseous plasmactyoma lesions (9731, 9734) –For histology 9731, primary site is bone –For histology 9734, primary site is NOT bone 500 Plasmacytoma, NOS (9731) –Primary site defaults to bone –Not stated if single or multiple lesions –Not stated if osseous or extraosseous 9

CS Extension 810 Plasma cell myeloma (9732) –Stated as multiple myeloma –Stated as plasma cell myeloma –Stated as myelomatosis 820 Myeloma, NOS (9732) –Stated as myeloma with no other description 999 Unknown –For codes 9731 and 9734 only –Code 999 not to be used for histology

CS Lymph nodes Applicable for histology code 9734 only Extraosseous plasmacytomas –Occur in numerous sites, including respiratory tract (most common), GI tract, bladder, CNS, breast thyroid, testis and parotid gland –These lesions may metastasize to regional lymph nodes 11

CS Lymph nodes Code 000: No evidence of regional lymph node involvement (code 9734) Code 100: Evidence of regional lymph node involvement (code 9734) Code 987: Use for histologies 9731 and 9732 Code 999: Unknown regional lymph node involvement; no documentation in record (code 9734) 12

# Positive, # Examined, LN Eval NOTE: –In v0203, these fields are automatically not applicable –These tables need to be replaced with the table that allows for recording the actual number of nodes examined and/or positive PLUS how the lymph node code was determined (for histology code 9734) –This error will be fixed in the next revision of CSv2 –For now, only code 99 will be acceptable for regional nodes positive and examined and code 9 for Lymph node eval 13

14 New Data Items Data ItemCodeExplanation Grade Path ValueBlankNot applicable Grade Path SystemBlankNot applicable Lymph vascular invasion (LVI)8Not applicable Mets at Dx-Bone8Not applicable Mets at Dx-Lung8Not applicable Mets at Dx-Brain8Not applicable Mets at Dx-Liver8Not applicable

SSF1: JAK2 (OBSOLETE) This SSF is OBSOLETE for histologies 9731, 9732 and 9734 All old data retained Only allowable code is 988 for cases: –Entered after v0203 update –Cases diagnosed 1/1/2011 and after 15

SSF2: Durie-Salmon Staging System Specific to multiple myeloma (9732) only Stage is based on: –Patient’s hemoglobin level –Serum calcium –Paraprotein levels –Urinary light chain excretions –Number of lytic bone lesions identified on skeletal survey Stages are: IA, IB, IIA, IIB, IIIA, IIIB –A or B designation based on the serum creatinine level 16

SSF2: Durie-Salmon Staging System Stage must be documented in record –If stage documented but not stated as “Durie Salmon”, can assume it is and code the appropriate stage –Do not calculate stage based on critiera (listed on previous slide) 17

SSF2: Durie-Salmon Staging System Code 010: Stage IA Code 020: Stage IB Code 030: Stage INOS Code 040: Stage IIA Code 050: Stage IIB Code 060: Stage IINOS 18

SSF2: Durie-Salmon Staging System Code 070: Stage IIIA Code 080: Stage IIIB Code 090: Stage IIINOS Code 987: Use for codes 9731 and 9734 Code 988: Can only be used for cases abstracted prior to v0203 or 1/1/2011 OR your standard setter does not require this SSF Code 999: Unknown, not documented in patient record 19

SSF3: Multiple Myeloma Terminology Specific to multiple myeloma (9732) only Variety of descriptive terms used to refer to early phases of myeloma These are reportable based on the 2010 Hematopoietic and Lymphoid Neoplasms coding rules This field captures the specific terminology used to describe the myeloma at TIME OF DIAGNOSIS 20

SSF3: Multiple Myeloma Terminology Code 000: Multiple myeloma/plasma cell myeloma with no other modifiers Code 010: Asymptomatic myeloma Code 020: Early myeloma, evolving myeloma Code 030: Inactive myeloma, idolent myeloma, smoldering myeloma 21

SSF3: Multiple Myeloma Terminology Code 080: Other terminology used to describe myeloma Code 100: Combination of terms in code Code 987: Use for codes 9731 and 9734 Code 988: Can only be used for cases abstracted prior to v0203 or 1/1/2011 OR your standard setter does not require this SSF Code 999: Unknown, not documented in patient record 22

23 Conclusion Histology codes 9731, 9732 and 9734 are now in the Myeloma Plasma Cell Disorder schema. Schema is applicable for all cases coded under v0203 or date of diagnosis 1/1/2011 and after Lymph nodes are to be coded for histology code 9734 SSF #1 is OBSOLETE and coded 988 for all cases coded in v0203 or date of diagnosis 1/1/2011 and after New SSF’s 2 and 3 are for histology code 9732 only

24 Other Resources The 2010 Hematopoietic and Lymphoid Neoplasm rules are available on the SEER website at: Use these rules to help determine reportability, grade, primary site and histology ONLY –Do not use these rules to apply stage

25 CAnswer Forum Submit questions to CS Forum –Located within the CAnswer Forum –Provides information for all –Allows tracking for educational purposes –Includes archives of Inquiry & Response System CS Forum: CS Web Site: